EMA Grants Orphan Medicinal Status to Eiger’s PAH Treatment Ubenimex
News, Pulmonary Hypertension
The European Medicines Agency (EMA) has granted Orphan Medicinal Product status to Eiger BioPharmaceuticals‘ Bestatin (ubenimex) for the treatment of pulmonary arterial hypertension (PAH). “We are very pleased with the EMA ... Read more